Changes in Beneficial Ownership · 4
Artiva Biotherapeutics, Inc.
ARTVNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-10-05
- Issuer
- Artiva Biotherapeutics, Inc.
- Issuer CIK
- 0001817241
- Trading symbol
- ARTV
Reporting owner 1
- Name
- Horan Christopher
- Reporting owner CIK
- 0001736819
- Relationship
- Officer
- Officer title
- Chief Tech Operations Officer
- Address
- C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO, CA, 92121
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-05 | S · Form 4 | 10,340[F1] | D | 6.8372 | 312,744 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.↩ 1
Signature 1
- Signed
- /s/ Jennifer Bush, Attorney-in-Fact
- Date
- 2026-10-06
Company context
Artiva is a clinical-stage biotechnology company that has focused on developing allogeneic natural killer (NK) cell therapies for autoimmune diseases. AlloNK® (AB-101), the Company’s lead development candidate, is a non-genetically modified, allogeneic, cryopreserved NK cell therapy that was evaluated in combination with B-cell-targeted monoclonal antibodies. On October 27, 2026, Artiva announced the discontinuation of further clinical development of AlloNK and the initiation of an evaluation of strategic alternatives. Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.